PL4054584T3 - Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2 - Google Patents

Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2

Info

Publication number
PL4054584T3
PL4054584T3 PL20884269.0T PL20884269T PL4054584T3 PL 4054584 T3 PL4054584 T3 PL 4054584T3 PL 20884269 T PL20884269 T PL 20884269T PL 4054584 T3 PL4054584 T3 PL 4054584T3
Authority
PL
Poland
Prior art keywords
inhibitor
mace
prevention
treatment
methods
Prior art date
Application number
PL20884269.0T
Other languages
English (en)
Inventor
Kenneth Eugene Lebioda
Christopher Ross Armstrong Halliday
Aziz Naeem KHAN
Original Assignee
Resverlogix Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp. filed Critical Resverlogix Corp.
Publication of PL4054584T3 publication Critical patent/PL4054584T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL20884269.0T 2019-11-05 2020-11-04 Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2 PL4054584T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
PCT/IB2020/000912 WO2021090061A1 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (1)

Publication Number Publication Date
PL4054584T3 true PL4054584T3 (pl) 2025-11-03

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20884269.0T PL4054584T3 (pl) 2019-11-05 2020-11-04 Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2

Country Status (17)

Country Link
US (1) US20220370452A1 (pl)
EP (1) EP4054584B1 (pl)
JP (1) JP7502811B2 (pl)
KR (1) KR20220098757A (pl)
CN (1) CN114650824A (pl)
AU (1) AU2020377539B2 (pl)
BR (1) BR112022008223A2 (pl)
CA (1) CA3160147A1 (pl)
DK (1) DK4054584T3 (pl)
ES (1) ES3042146T3 (pl)
FI (1) FI4054584T3 (pl)
IL (1) IL292696A (pl)
MX (1) MX2022005029A (pl)
PL (1) PL4054584T3 (pl)
PT (1) PT4054584T (pl)
TW (1) TWI867086B (pl)
WO (1) WO2021090061A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR
WO2022155303A1 (en) * 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MX2016002178A (es) * 2013-08-21 2016-06-06 Resverlogix Corp Composiciones y metodos terapeuticos para la regresion acelerada de placa.
AU2014310369A1 (en) * 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
EP3268007B1 (en) * 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
PE20181068A1 (es) * 2015-10-02 2018-07-04 Dana Farber Cancer Inst Inc Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR

Also Published As

Publication number Publication date
DK4054584T3 (en) 2025-09-01
EP4054584A4 (en) 2023-11-08
BR112022008223A2 (pt) 2022-09-06
CA3160147A1 (en) 2021-05-14
ES3042146T3 (en) 2025-11-18
KR20220098757A (ko) 2022-07-12
AU2020377539A1 (en) 2022-05-19
US20220370452A1 (en) 2022-11-24
AU2020377539B2 (en) 2025-05-29
MX2022005029A (es) 2022-07-12
TW202131924A (zh) 2021-09-01
EP4054584B1 (en) 2025-07-09
CN114650824A (zh) 2022-06-21
JP7502811B2 (ja) 2024-06-19
IL292696A (en) 2022-07-01
PT4054584T (pt) 2025-07-16
FI4054584T3 (fi) 2025-08-22
EP4054584A1 (en) 2022-09-14
WO2021090061A1 (en) 2021-05-14
JP2023500685A (ja) 2023-01-10
TWI867086B (zh) 2024-12-21

Similar Documents

Publication Publication Date Title
SG11202105158VA (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
DK4054584T3 (en) Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CA3249318A1 (en) PARP1 INHIBITORS AND THEIR USES
IL320829A (en) PARP1 inhibitors and their uses
IL280591A (en) Methods for delaying the onset of new type 2 diabetes and slowing the progression and treatment of type 2 diabetes
PL4094763T3 (pl) Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem
GB202204420D0 (en) Crypto-erasure via internal and/or external action
IL275925A (en) Prevention and treatment of organ damage
ZA202202617B (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
SG11202107720UA (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
IL314208A (en) Nanobody-drug combinations and their uses
GB202103578D0 (en) Prevention and treatment of infections including those caused by coronavirus
PL4069278T3 (pl) Sposoby i kompozycje do zapobiegania cukrzycy typu 1
IL276905A (en) Treatment and prevention of preeclampsia
EP4052443A4 (en) COMBINED TOKEN AND VALUE EVALUATION PROCESSING
HK40076178A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
EP4178359A4 (en) COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS
HUE059233T2 (hu) Vegyület epizootius nyúl-enteropátia kezelésében és/vagy megelõzésében való alkalmazásra
GB2625512B (en) Triggered-producer and triggered-consumer instructions
PL4061399T3 (pl) Działanie insulinotropowe i glukagonotropowe beta-laktoglobuliny
IL321017A (en) Inhibitors and/or decomposers containing 3-fluoro-4-hydroxybenzmide and uses thereof
IL289425A (en) The compositions containing cannabidiol for use in the treatment and prevention of inflammatory blockage of the bronchi
HK40113727A (en) Methods for the prevention and treatment of synucleinopathies
GB202210704D0 (en) Biofilm prevention and treatment